病例报告:通过胺基氨酸辅助治疗改善了耐火性功能性发作,抑郁和生活质量
Elena Argento1,2, Egiroh Omene3, Alexandria H Jaeger1
1Numinus Wellness Inc., Vancouver, BC, Canada.
Frontiers in neuroscience
|June 28, 2023
概括
胺基辅助疗法对治疗功能性发作,一种功能神经障碍 (FND) 的治疗有希望. 这种新的方法显著降低了耐药症状和同时出现抑郁症和PTSD的患者的发作频率和严重程度.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 神经学 神经学
背景情况:
- 功能性是功能神经障碍 (FND) 的主要亚型,导致显著的神经障碍.
- FND涉及运动,感觉或认知方面的改变,包括具有心理基础的类似发作的情节.
- 目前用于功能性的治疗方法缺乏一致的疗效,需要研究新的治疗方法.
研究的目的:
- 调查胺辅助疗法的潜力,作为耐火性功能性发作的新疗法.
- 报告凯胺辅助治疗改善功能性发作的第一个案例.
主要方法:
- 一名51岁的女性患有日常耐火性功能发作,主要抑郁症 (MDD) 和创伤后应激障碍 (PTSD) 接受了胺辅助治疗.
- 治疗包括3周的密集治疗,随后是20周的间歇性胺和心理治疗.
主要成果:
- 患者的功能性发作频率和严重程度显著降低.
- 在抑郁症状和功能能力得分方面观察到明显的改善.
- 这一案例是首次报告使用胺胺辅助疗法改善功能性的案例.
结论:
- 基他胺辅助疗法可能是功能性发作的可行的治疗选择.
- 需要进一步进行严格的研究,以探索胺辅助治疗对功能性发作和其他FND症状的疗效.
相关概念视频
Electroconvulsive Therapy
75
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
75
Antiepileptic Drugs: Potassium Channel Activators
217
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
217
Psychosis: Goals of Pharmacotherapy
171
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
171
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
351
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
351
Epilepsy and Seizures: Overview
228
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
228
Drug Therapy
74
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
74


